Latest Headlines

1. Samsung Biologics Expands U.S. Manufacturing Capabilities With Strategic Acquisition Of Human Genome Sciences From GSK 12/22/2025

   This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.

2. Sanofi Toronto Equipment Assets Auction Announced For January 2026 12/19/2025

   Federal Equipment Company, a trusted global provider of surplus pharmaceutical and chemical processing equipment, announced it will conduct a two-day online auction on behalf of Sanofi featuring quality process and laboratory equipment surplus to the company’s ongoing operational needs.

3. Alnylam Announces $250M Investment To Expand U.S. Manufacturing Capacity In Massachusetts For RNAi Therapeutics 12/18/2025

   Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs, and position Alnylam to support future launches across its growing pipeline of potential new medicines.

4. Minaris And Cell And Gene Therapy Catapult Announce Collaboration To Advance Delivery Methods For Cell And Gene Therapies 12/18/2025

   Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Cell and Gene Therapy Catapult (CGT Catapult), an independent technology and innovation organization specializing in the advancement of the CGT industry, today announced a collaboration to develop CGT delivery technologies to enable more robust manufacturing processes, improved quality, and lower cost of goods.

5. Asimov Launches CHO Edge Rapid Pools To Bridge Biologics Discovery And CMC With Predictive Stable Expression 12/16/2025

   Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of CHO Edge Rapid Pools, a high-throughput stable CHO expression system that brings CMC-grade performance and assurance to biologics discovery teams.

6. Bora Pharmaceuticals And Corealis Pharma Forge Strategic Alliance To Deliver Seamless, End-To-End Oral Solid Dose Development 12/9/2025

   Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc., a leading early-phase Contract Development Manufacturing Organization (CDMO), have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and manufacturing. The collaboration will simplify the drug development process and provide a more scalable pathway to commercialization via a single continuum.

7. Late-Model Lab & Bioprocess Equipment From Premier Biopharma Facility To Be Offered For Sale December 4–9, 2025 12/8/2025
8. Andelyn Biosciences Announces Partnership With Jaguar Gene Therapy To Provide Late-Stage PPQ Manufacturing 12/8/2025

   Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Jaguar Gene Therapy to perform late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, an investigational gene therapy targeting SHANK3 haploinsufficiency which is clinically diagnosed as Phelan-McDermid syndrome (PMS), a leading monogenic cause of autism spectrum disorder (ASD).

9. Bora Pharmaceuticals Marks Five Years In Mississauga, Canada, Strengthening Its Commitment To Onshore And Global CDMO Excellence 12/5/2025

   Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today celebrates the five-year anniversary of its Mississauga, Ontario, Canada facility, a key hub in the company’s North American operations and a cornerstone of its expanding international CDMO network. The milestone will be celebrated onsite with employees, partners, and community stakeholders.

10. medac CDMO Supports Urogen Pharma's Advancement Of UGN-103 11/24/2025

    This collaboration reflects a commitment to advancing meaningful therapies and ensuring patients worldwide gain access to effective, reliable treatment options.